Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.05 Billion DKK | 123.99% |
| 2022 | 3.15 Billion DKK | 66.02% |
| 2021 | 1.89 Billion DKK | 2.46% |
| 2020 | 1.85 Billion DKK | 179.61% |
| 2019 | 662.48 Million DKK | 32.33% |
| 2018 | 500.61 Million DKK | -63.46% |
| 2017 | 1.37 Billion DKK | 36.1% |
| 2016 | 1 Billion DKK | -1.35% |
| 2015 | 1.02 Billion DKK | -16.13% |
| 2014 | 1.21 Billion DKK | 0.36% |
| 2013 | 1.21 Billion DKK | 19.27% |
| 2012 | 1.01 Billion DKK | 94.16% |
| 2011 | 523.6 Million DKK | 66.71% |
| 2010 | 314.07 Million DKK | 319.98% |
| 2009 | 74.78 Million DKK | -64.19% |
| 2008 | 208.8 Million DKK | -37.13% |
| 2007 | 332.1 Million DKK | 89.46% |
| 2006 | 175.29 Million DKK | -29.2% |
| 2005 | 247.59 Million DKK | 50.26% |
| 2004 | 164.78 Million DKK | -67.35% |
| 2003 | 504.64 Million DKK | 316.79% |
| 2002 | 121.07 Million DKK | 0.0% |
| 2001 | - DKK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.42 Billion DKK | 71.68% |
| 2024 Q1 | 831.47 Million DKK | -66.05% |
| 2023 Q2 | 1.98 Billion DKK | 58.67% |
| 2023 FY | 7.05 Billion DKK | 123.99% |
| 2023 Q3 | 1.37 Billion DKK | -30.72% |
| 2023 Q4 | 2.44 Billion DKK | 77.96% |
| 2023 Q1 | 1.25 Billion DKK | -2.98% |
| 2022 FY | 3.15 Billion DKK | 66.02% |
| 2022 Q3 | 1 Billion DKK | 86.99% |
| 2022 Q1 | 320.05 Million DKK | -41.16% |
| 2022 Q2 | 536.69 Million DKK | 67.69% |
| 2022 Q4 | 1.29 Billion DKK | 28.59% |
| 2021 FY | 1.89 Billion DKK | 2.46% |
| 2021 Q1 | 535.25 Million DKK | 133.82% |
| 2021 Q2 | 369.99 Million DKK | -30.87% |
| 2021 Q3 | 448.65 Million DKK | 21.26% |
| 2021 Q4 | 543.96 Million DKK | 21.24% |
| 2020 Q2 | 699.57 Million DKK | 91.45% |
| 2020 Q3 | 558.48 Million DKK | -20.17% |
| 2020 Q4 | 228.91 Million DKK | -59.01% |
| 2020 FY | 1.85 Billion DKK | 179.61% |
| 2020 Q1 | 365.4 Million DKK | 25.92% |
| 2019 Q1 | 126.83 Million DKK | -30.02% |
| 2019 Q2 | 101.36 Million DKK | -20.08% |
| 2019 Q3 | 144.09 Million DKK | 42.16% |
| 2019 FY | 662.48 Million DKK | 32.33% |
| 2019 Q4 | 290.19 Million DKK | 101.38% |
| 2018 Q2 | 86.34 Million DKK | 664.48% |
| 2018 FY | 500.61 Million DKK | -63.46% |
| 2018 Q1 | 11.29 Million DKK | -72.39% |
| 2018 Q4 | 181.25 Million DKK | -18.26% |
| 2018 Q3 | 221.73 Million DKK | 156.81% |
| 2017 FY | 1.37 Billion DKK | 36.1% |
| 2017 Q3 | 734.27 Million DKK | 84.83% |
| 2017 Q2 | 397.27 Million DKK | 100.95% |
| 2017 Q1 | 197.69 Million DKK | -52.4% |
| 2017 Q4 | 40.9 Million DKK | -94.43% |
| 2016 Q4 | 415.33 Million DKK | -8.17% |
| 2016 Q2 | 116.55 Million DKK | 416.7% |
| 2016 Q1 | 22.55 Million DKK | -92.9% |
| 2016 FY | 1 Billion DKK | -1.35% |
| 2016 Q3 | 452.29 Million DKK | 288.05% |
| 2015 FY | 1.02 Billion DKK | -16.13% |
| 2015 Q4 | 317.54 Million DKK | 301.45% |
| 2015 Q3 | 79.1 Million DKK | -79.67% |
| 2015 Q2 | 389.1 Million DKK | 65.72% |
| 2015 Q1 | 234.8 Million DKK | -56.62% |
| 2014 Q2 | 164.5 Million DKK | -42.46% |
| 2014 Q4 | 541.21 Million DKK | 140.33% |
| 2014 Q3 | 225.2 Million DKK | 36.9% |
| 2014 FY | 1.21 Billion DKK | 0.36% |
| 2014 Q1 | 285.9 Million DKK | -15.29% |
| 2013 Q3 | 318.9 Million DKK | -8.99% |
| 2013 Q4 | 337.5 Million DKK | 5.83% |
| 2013 FY | 1.21 Billion DKK | 19.27% |
| 2013 Q1 | 205.7 Million DKK | -22.91% |
| 2013 Q2 | 350.4 Million DKK | 70.35% |
| 2012 FY | 1.01 Billion DKK | 94.16% |
| 2012 Q4 | 266.83 Million DKK | -12.34% |
| 2012 Q3 | 304.4 Million DKK | 9.65% |
| 2012 Q2 | 277.6 Million DKK | 65.44% |
| 2012 Q1 | 167.8 Million DKK | -54.49% |
| 2011 Q4 | 368.7 Million DKK | 279.71% |
| 2011 FY | 523.6 Million DKK | 66.71% |
| 2011 Q1 | 28.6 Million DKK | -69.85% |
| 2011 Q2 | 29.2 Million DKK | 2.1% |
| 2011 Q3 | 97.1 Million DKK | 232.53% |
| 2010 Q2 | 161.9 Million DKK | 1099.26% |
| 2010 Q1 | 13.5 Million DKK | -37.45% |
| 2010 Q4 | 94.87 Million DKK | 117.1% |
| 2010 FY | 314.07 Million DKK | 319.98% |
| 2010 Q3 | 43.7 Million DKK | -73.01% |
| 2009 Q2 | 15.8 Million DKK | -7.6% |
| 2009 Q1 | 17.1 Million DKK | 0.0% |
| 2009 FY | 74.78 Million DKK | -64.19% |
| 2009 Q4 | 21.58 Million DKK | 6.32% |
| 2009 Q3 | 20.3 Million DKK | 28.48% |
| 2008 FY | 208.8 Million DKK | -37.13% |
| 2007 FY | 332.1 Million DKK | 89.46% |
| 2006 FY | 175.29 Million DKK | -29.2% |
| 2005 FY | 247.59 Million DKK | 50.26% |
| 2004 FY | 164.78 Million DKK | -67.35% |
| 2003 FY | 504.64 Million DKK | 316.79% |
| 2002 FY | 121.07 Million DKK | 0.0% |
| 2001 FY | - DKK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ALK-Abelló A/S | 4.82 Billion DKK | -46.296% |
| Genmab A/S | 16.47 Billion DKK | 57.161% |
| Gubra A/S | 205 Million DKK | -3342.513% |
| Novo Nordisk A/S | 232.26 Billion DKK | 96.961% |
| Orphazyme A/S | - DKK | -Infinity% |
| Pharma Equity Group A/S | - DKK | -Infinity% |
| Zealand Pharma A/S | 342.78 Million DKK | -1958.801% |